Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H14N4O2.ClH |
Molecular Weight | 210.662 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.N[C@@H](CCCNC(N)=N)C(O)=O
InChI
InChIKey=KWTQSFXGGICVPE-WCCKRBBISA-N
InChI=1S/C6H14N4O2.ClH/c7-4(5(11)12)2-1-3-10-6(8)9;/h4H,1-3,7H2,(H,11,12)(H4,8,9,10);1H/t4-;/m0./s1
L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and as a treatment for erectile dysfunction in men. L-arginine is a nonessential amino acid that may play an important role in the treatment of heart disease due to its block arterial plaque buildup, blood clots, platelet clumping, and to increase blood flow through the coronary artery. L-arginine is commonly sold as a health supplement claiming to improve vascular health and treat erectile dysfunction in men. L-arginine, which is promoted as a human growth stimulant, has also been used in bodybuilding. In the 1800s, it was first isolated from animal horn.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q5T6X5 Gene ID: 222545.0 Gene Symbol: GPRC6A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628 |
44.1 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Preventing | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
310 μM |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
6219 μM |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
882 μM |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24788 M × min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
265435 M × min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
38223 M × min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
77.5 min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
41.6 min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
59.6 min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% EXPERIMENT https://www.jci.org/articles/view/103568 |
ARGININE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Disc. AE: Cardiopulmonary arrest, Metabolic acidosis... AEs leading to discontinuation/dose reduction: Cardiopulmonary arrest Sources: Page: p.621Metabolic acidosis (acute) Hyponatremia (severe) |
200 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 200 mg/kg, 3 times / day Route: oral Route: multiple Dose: 200 mg/kg, 3 times / day Sources: Page: p.63 |
unhealthy, 24 n = 11 Health Status: unhealthy Condition: Cystic fibrosis Age Group: 24 Sex: M+F Population Size: 11 Sources: Page: p.63 |
|
15 g 2 times / day multiple, oral Studied dose Dose: 15 g, 2 times / day Route: oral Route: multiple Dose: 15 g, 2 times / day Sources: Page: p.1 |
healthy, 34 ± 2.6 n = 12 Health Status: healthy Condition: Dietary supplementation Age Group: 34 ± 2.6 Sex: M+F Population Size: 12 Sources: Page: p.1 |
|
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: Page: p.200 |
unhealthy, 43± 16 n = 10 Health Status: unhealthy Condition: Hypercholesterolaemia Age Group: 43± 16 Sex: M+F Population Size: 10 Sources: Page: p.200 |
DLT: Gastrointestinal discomfort... Dose limiting toxicities: Gastrointestinal discomfort (20%) Sources: Page: p.200 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cardiopulmonary arrest | Disc. AE | 3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Metabolic acidosis | acute Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Hyponatremia | severe Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Gastrointestinal discomfort | 20% DLT |
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: Page: p.200 |
unhealthy, 43± 16 n = 10 Health Status: unhealthy Condition: Hypercholesterolaemia Age Group: 43± 16 Sex: M+F Population Size: 10 Sources: Page: p.200 |
PubMed
Title | Date | PubMed |
---|---|---|
Prevalence of mutations causing retinitis pigmentosa and other inherited retinopathies. | 2001 |
|
Purification and characterization of calobin II, a second type of thrombin-like enzyme from Agkistrodon caliginosus (Korean viper). | 2001 Apr |
|
Internal ribosome entry site-mediated translation of a mammalian mRNA is regulated by amino acid availability. | 2001 Apr 13 |
|
Signal-binding specificity of the mu4 subunit of the adaptor protein complex AP-4. | 2001 Apr 20 |
|
Nucleocytoplasmic shuttling of heterodimeric splicing factor U2AF. | 2001 Apr 20 |
|
Fructose-6-phosphate aldolase is a novel class I aldolase from Escherichia coli and is related to a novel group of bacterial transaldolases. | 2001 Apr 6 |
|
Amino acid residues outside of the pore region contribute to N-type calcium channel permeation. | 2001 Feb 23 |
|
Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. | 2001 Feb 23 |
|
Early glycation products produce pentosidine cross-links on native proteins. novel mechanism of pentosidine formation and propagation of glycation. | 2001 Feb 9 |
|
Influence of microcystin-YR and nodularin on the activity of some proteolytic enzymes in mouse liver. | 2001 Feb-Mar |
|
The nutritional management of urea cycle disorders. | 2001 Jan |
|
Current strategies for the management of neonatal urea cycle disorders. | 2001 Jan |
|
Fibroblast growth factor-2 stimulates endothelial nitric oxide synthase expression and inhibits apoptosis by a nitric oxide-dependent pathway in Nb2 lymphoma cells. | 2001 Jan |
|
Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro. | 2001 Jan |
|
Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. | 2001 Jan |
|
A metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the deleterious effects of lipopolysaccharide in rats. | 2001 Jan |
|
Relationship between flow rate and NO production in postnatal mesenteric arteries. | 2001 Jan |
|
The common Arg972 polymorphism in insulin receptor substrate-1 causes apoptosis of human pancreatic islets. | 2001 Jan |
|
Glutamine metabolism to glucosamine is necessary for glutamine inhibition of endothelial nitric oxide synthesis. | 2001 Jan 15 |
|
Amino acid residues in ribonuclease MC1 from bitter gourd seeds which are essential for uridine specificity. | 2001 Jan 16 |
|
Structure and organization of bacteriophage Pf3 probed by Raman and ultraviolet resonance Raman spectroscopy. | 2001 Jan 16 |
|
Insights into the molecular basis for the carbenicillinase activity of PSE-4 beta-lactamase from crystallographic and kinetic studies. | 2001 Jan 16 |
|
Upregulation of the nitric oxide-cGMP pathway in aged myocardium: physiological response to l-arginine. | 2001 Jan 19 |
|
A proposed common structure of substrates bound to mitochondrial processing peptidase. | 2001 Jan 19 |
|
Site-specific single amino acid changes to Lys or Arg in the central region of the movement protein of a hybrid bromovirus are required for adaptation to a nonhost. | 2001 Jan 5 |
|
Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. | 2001 Jan 5 |
|
The function of Arg-94 in the oxidation and decarboxylation of glutaryl-CoA by human glutaryl-CoA dehydrogenase. | 2001 Jan 5 |
|
L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. | 2001 Jan 5 |
|
C60-Fullerene monomalonate adducts selectively inactivate neuronal nitric oxide synthase by uncoupling the formation of reactive oxygen intermediates from nitric oxide production. | 2001 Jan 9 |
|
Translocation of jellyfish green fluorescent protein via the Tat system of Escherichia coli and change of its periplasmic localization in response to osmotic up-shock. | 2001 Mar 16 |
|
Identification and analysis of the acyl carrier protein (ACP) docking site on beta-ketoacyl-ACP synthase III. | 2001 Mar 16 |
|
The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. | 2001 Mar 23 |
|
Effect of oxygen on induction of the cystine transporter by bacterial lipopolysaccharide in mouse peritoneal macrophages. | 2001 Mar 30 |
|
Peptide leucine arginine, a potent immunomodulatory peptide isolated and structurally characterized from the skin of the Northern Leopard frog, Rana pipiens. | 2001 Mar 30 |
|
The role of nitric oxide on the relaxations of rabbit corpus cavernosum induced by Androctonus australis and Buthotus judaicus scorpion venoms. | 2001 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npc/l-arginine.html
Curator's Comment: I.V route is possible: The recommended adult dose is 30 g arginine hydrochloride (300 mL of R-Gene 10) administered by intravenous infusion over 30 minutes. The total dose should not exceed 30 g arginine hydrochloride.
https://www.drugs.com/dosage/r-gene-10.html
L-arginine has been studied at oral doses of 6 to 30 g/day for a variety of conditions. Many formulations have been used.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628
A strong inward current in X. laevis oocytes expressing 5.24 (C terminus of the homologous goldfish 5.24 receptor) when L-Arg (L-arginine) was applied at 10 uM. When testing chimera h6A/5.24 (h6A/5.24, containing the ligand binding amino-terminal domain (ATD) of hGPRC6A with the signal transducing transmembrane and C terminus of the homologous goldfish 5.24 receptor) in this system, the responses were obtained with L-Arg at 100 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
B05XB01
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
||
|
WHO-VATC |
QB05XB01
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
||
|
NCI_THESAURUS |
C231
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
7914
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL1200381
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
C29606
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
1042601
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
DTXSID20883650
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
F7LTH1E20Y
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
m2040
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | Merck Index | ||
|
1119-34-2
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
203450
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
DBSALT000869
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
SUB22706
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
1549
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
89918
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | RxNorm | ||
|
66250
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
SUB00579MIG
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
C1505
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
CONCEPT | Dietary Supplement | ||
|
214-275-1
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
SUB30001
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
100000085170
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY | |||
|
F7LTH1E20Y
Created by
admin on Fri Dec 15 15:16:30 GMT 2023 , Edited by admin on Fri Dec 15 15:16:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD